Advertisement

Attention-Deficit Hyperactivity Disorder and Autism Spectrum Disorder

  • Samuele Cortese
Chapter

Abstract

Previous versions of the Diagnostic and Statistical Manual of Mental Disorders (DSM) did not allow the possibility of diagnosing attention-deficit/hyperactivity disorder (ADHD) in individuals with autism spectrum disorder (ASD). However, this veto has been removed in the current version of the DSM (DSM-5), highlighting the need for screening and appropriately managing, when present, symptoms of ADHD (i.e., inattention and/or hyperactivity/impulsivity) in individuals with ASD. Evidence from neuroimaging and genetic studies points to shared but also specific neurobiological underpinnings across the two disorders. While there is a large body of research on the pharmacological and non-pharmacological treatments of ADHD, evidence on the management of ADHD symptoms in individuals with ASD needs further investigation. Future studies should explore pathophysiologically based, rather than symptomatic, intervention strategies for ADHD associated with ASD.

Keywords

Autism Spectrum Disorder Autism Spectrum Disorder Diffusion Tensor Imaging ADHD Symptom Cognitive Training 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Adler LD, Nierenberg AA (2010) Review of medication adherence in children and adults with ADHD. Postgrad Med 122:184–191CrossRefPubMedGoogle Scholar
  2. American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders, 5th edn, DSM-5. American Psychiatric Publishing, Washington, DCGoogle Scholar
  3. Anderson GM, Scahill L, McCracken JT, McDougle CJ, Aman MG, Tierney E et al (2007) Effects of short- and long-term risperidone treatment on prolactin levels in children with autism. Biol Psychiatry 61:545–550CrossRefPubMedGoogle Scholar
  4. Antshel KM, Zhang-James Y, Faraone SV (2013) The comorbidity of ADHD and autism spectrum disorder. Expert Rev Neurother 13:1117–1128CrossRefPubMedGoogle Scholar
  5. Biederman J, Faraone SV (2005) Attention-deficit hyperactivity disorder. Lancet 366:237–248CrossRefPubMedGoogle Scholar
  6. Castells X, Ramos-Quiroga JA, Bosch R, Nogueira M, Casas M (2011a) Amphetamines for Attention Deficit Hyperactivity Disorder (ADHD) in adults. Cochrane Database Syst Rev (6):CD007813Google Scholar
  7. Castells X, Ramos-Quiroga JA, Rigau D, Bosch R, Nogueira M, Vidal X et al (2011a) Efficacy of methylphenidate for adults with attention-deficit hyperactivity disorder: a meta-regression analysis. CNS Drugs 25:157–169CrossRefPubMedGoogle Scholar
  8. Cheng JY, Chen RY, Ko JS, Ng EM (2007) Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis. Psychopharmacology (Berl) 194:197–209CrossRefGoogle Scholar
  9. Cohen J (1992) A power primer. Psychol Bull 112:155–159CrossRefPubMedGoogle Scholar
  10. Cohen IL, Campbell M, Posner D, Small AM, Triebel D, Anderson LT (1980) Behavioral effects of haloperidol in young autistic children. An objective analysis using a within-subjects reversal design. J Am Acad Child Psychiatry 19:665–677CrossRefPubMedGoogle Scholar
  11. Conners CK, Sitarenios G, Parker JD, Epstein JN (1998a) Revision and restandardization of the Conners Teacher Rating Scale (CTRS-R): factor structure, reliability, and criterion validity. J Abnorm Child Psychol 26:279–291CrossRefPubMedGoogle Scholar
  12. Conners CK, Sitarenios G, Parker JD, Epstein JN (1998b) The revised Conners’ Parent Rating Scale (CPRS-R): factor structure, reliability, and criterion validity. J Abnorm Child Psychol 26:257–268CrossRefPubMedGoogle Scholar
  13. Cortese S, Holtmann M, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M et al (2013) Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. J Child Psychol Psychiatry 54:227–246CrossRefPubMedGoogle Scholar
  14. Cortese S, Ferrin M, Brandeis D, Buitelaar J, Daley D, Dittmann RW et al (2015a) Cognitive training for attention-deficit/hyperactivity disorder: meta-analysis of clinical and neuropsychological outcomes from randomized controlled trials. J Am Acad Child Adolesc Psychiatry 54:164–174CrossRefPubMedPubMedCentralGoogle Scholar
  15. Cortese S, Panei P, Arcieri R, Germinario EA, Capuano A, Margari L et al (2015b) Safety of methylphenidate and atomoxetine in children with Attention-Deficit/Hyperactivity Disorder (ADHD): data from the Italian National ADHD Registry. CNS Drugs 29(10):865–77Google Scholar
  16. Cunill R, Castells X, Tobias A, Capella D (2013) Atomoxetine for attention deficit hyperactivity disorder in the adulthood: a meta-analysis and meta-regression. Pharmacoepidemiol Drug Saf 22:961–969PubMedGoogle Scholar
  17. Daley D, Van der Oord S, Ferrin M, Danckaerts M, Doepfner M, Cortese S et al (2014) Behavioral interventions in attention-deficit/hyperactivity disorder: a meta-analysis of randomized controlled trials across multiple outcome domains. J Am Acad Child Adolesc Psychiatry 53:835–847CrossRefPubMedGoogle Scholar
  18. Dinnissen M, Dietrich A, van den Hoofdakker BJ, Hoekstra PJ (2015) Clinical and pharmacokinetic evaluation of risperidone for the management of autism spectrum disorder. Expert Opin Drug Metab Toxicol 11:111–124PubMedGoogle Scholar
  19. Dougherty CC, Evans DW, Myers SM, Moore GJ, Michael AM (2015) A comparison of structural brain imaging findings in autism spectrum disorder and Attention-Deficit Hyperactivity Disorder. Neuropsychol Rev 26(1):25–43Google Scholar
  20. Elbe D, Lalani Z (2012) Review of the pharmacotherapy of irritability of autism. J Can Acad Child Adolesc Psychiatry 21:130–146PubMedPubMedCentralGoogle Scholar
  21. Faraone SV, Biederman J (2002) Efficacy of Adderall for attention-deficit/hyperactivity disorder: a meta-analysis. J Atten Disord 6:69–75CrossRefPubMedGoogle Scholar
  22. Faraone SV, Buitelaar J (2010) Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry 19:353–364CrossRefPubMedGoogle Scholar
  23. Faraone SV, Biederman J, Mick E (2006a) The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med 36:159–165CrossRefPubMedGoogle Scholar
  24. Faraone SV, Biederman J, Spencer TJ, Aleardi M (2006b) Comparing the efficacy of medications for ADHD using meta-analysis. Med Gen Med 8:4Google Scholar
  25. Feldman HM, Reiff MI (2014) Clinical practice. Attention deficit-hyperactivity disorder in children and adolescents. N Engl J Med 370:838–846CrossRefPubMedGoogle Scholar
  26. Ghanizadeh A (2013) Atomoxetine for treating ADHD symptoms in autism: a systematic review. J Atten Disord 17:635–640CrossRefPubMedGoogle Scholar
  27. Gray CA (1993) The original social stories book. Future Horizons, ArlingtonGoogle Scholar
  28. Grzadzinski R, Di MA, Brady E, Mairena MA, O’Neale M, Petkova E et al (2011) Examining autistic traits in children with ADHD: does the autism spectrum extend to ADHD? J Autism Dev Disord 41:1178–1191CrossRefPubMedPubMedCentralGoogle Scholar
  29. Hanwella R, Senanayake M, de Silva V (2011) Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis. BMC Psychiatry 11:176CrossRefPubMedPubMedCentralGoogle Scholar
  30. Horner RH, Carr EG, Strain PS, Todd AW, Reed HK (2002) Problem behavior interventions for young children with autism: a research synthesis. J Autism Dev Disord 32:423–446CrossRefPubMedGoogle Scholar
  31. Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P et al (1997) Schedule for affective disorders and schizophrenia for school-age children-present and lifetime version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 36:980–988CrossRefPubMedGoogle Scholar
  32. Kirino E (2014) Efficacy and tolerability of pharmacotherapy options for the treatment of irritability in autistic children. Clin Med Insights Pediatr 8:17–30CrossRefPubMedPubMedCentralGoogle Scholar
  33. Koesters M, Becker T, Kilian R, Fegert JM, Weinmann S (2009) Limits of meta-analysis: methylphenidate in the treatment of adult attention-deficit hyperactivity disorder. J Psychopharmacol 23:733–744CrossRefPubMedGoogle Scholar
  34. Kovshoff H, Williams S, Vrijens M, Danckaerts M, Thompson M, Yardley L et al (2012) The decisions regarding ADHD management (DRAMa) study: uncertainties and complexities in assessment, diagnosis and treatment, from the clinician’s point of view. Eur Child Adolesc Psychiatry 21:87–99CrossRefPubMedGoogle Scholar
  35. Kratochvil CJ, Milton DR, Vaughan BS, Greenhill LL (2008) Acute atomoxetine treatment of younger and older children with ADHD: a meta-analysis of tolerability and efficacy. Child Adolesc Psychiatry Ment Health 2:25CrossRefPubMedPubMedCentralGoogle Scholar
  36. Lecavalier L (2006) Behavioral and emotional problems in young people with pervasive developmental disorders: relative prevalence, effects of subject characteristics, and empirical classification. J Autism Dev Disord 36:1101–1114CrossRefPubMedGoogle Scholar
  37. Maia CR, Cortese S, Caye A, Deakin TK, Polanczyk GV, Polanczyk CA et al (2014) Long-Term efficacy of methylphenidate immediate-release for the treatment of childhood ADHD: a systematic review and meta-analysis. J Atten Disord, in pressGoogle Scholar
  38. Marcus RN, Owen R, Kamen L, Manos G, McQuade RD, Carson WH et al (2009) A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry 48:1110–1119CrossRefPubMedGoogle Scholar
  39. Martin A, Scahill L, Anderson GM, Aman M, Arnold LE, McCracken J et al (2004) Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data. Am J Psychiatry 161:1125–1127CrossRefPubMedGoogle Scholar
  40. McDougle CJ, Scahill L, Aman MG, McCracken JT, Tierney E, Davies M et al (2005) Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry 162:1142–1148CrossRefPubMedGoogle Scholar
  41. Molina BS, Hinshaw SP, Swanson JM, Arnold LE, Vitiello B, Jensen PS et al (2009) MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study. J Am Acad Child Adolesc Psychiatry 48(5):484–500CrossRefPubMedPubMedCentralGoogle Scholar
  42. Nass RD (2005) Evaluation and assessment issues in the diagnosis of attention deficit hyperactivity disorder. Semin Pediatr Neurol 12:200–216CrossRefPubMedGoogle Scholar
  43. Nijmeijer JS, Arias-Vasquez A, Rommelse NN, Altink ME, Anney RJ, Asherson P et al (2010) Identifying loci for the overlap between attention-deficit/hyperactivity disorder and autism spectrum disorder using a genome-wide QTL linkage approach. J Am Acad Child Adolesc Psychiatry 49:675–685PubMedPubMedCentralGoogle Scholar
  44. Owen R, Sikich L, Marcus RN, Corey-Lisle P, Manos G, McQuade RD et al (2009) Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics 124:1533–1540CrossRefPubMedGoogle Scholar
  45. Pliszka S (2007) Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 46:894–921CrossRefPubMedGoogle Scholar
  46. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA (2007) The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 164:942–948CrossRefPubMedGoogle Scholar
  47. Polanczyk GV, Willcutt EG, Salum GA, Kieling C, Rohde LA (2014) ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis. Int J Epidemiol 43(2):434–42Google Scholar
  48. Proal E, Gonzalez-Olvera J, Blancas AS, Chalita PJ, Castellanos FX (2013) Neurobiology of autism and attention deficit hyperactivity disorder by means of neuroimaging techniques: convergences and divergences. Rev Neurol 57(Suppl 1):S163–S175PubMedPubMedCentralGoogle Scholar
  49. Reichow B, Volkmar FR, Bloch MH (2013) Systematic review and meta-analysis of pharmacological treatment of the symptoms of attention-deficit/hyperactivity disorder in children with pervasive developmental disorders. J Autism Dev Disord 43:2435–2441CrossRefPubMedPubMedCentralGoogle Scholar
  50. Reiersen AM, Constantino JN, Grimmer M, Martin NG, Todd RD (2008) Evidence for shared genetic influences on self-reported ADHD and autistic symptoms in young adult Australian twins. Twin Res Hum Genet 11:579–585CrossRefPubMedPubMedCentralGoogle Scholar
  51. Rhodes C (2014) Do Social Stories help to decrease disruptive behaviour in children with autistic spectrum disorders? A review of the published literature. J Intellect Disabil 18:35–50CrossRefPubMedGoogle Scholar
  52. Scahill L, Aman MG, McDougle CJ, Arnold LE, McCracken JT, Handen B et al (2009) Trial design challenges when combining medication and parent training in children with pervasive developmental disorders. J Autism Dev Disord 39:720–729CrossRefPubMedPubMedCentralGoogle Scholar
  53. Schachter HM, Pham B, King J, Langford S, Moher D (2001) How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. CMAJ 165:1475–1488PubMedPubMedCentralGoogle Scholar
  54. Schwartz S, Correll CU (2014) Efficacy and safety of atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: results from a comprehensive meta-analysis and metaregression. J Am Acad Child Adolesc Psychiatry 53:174–187CrossRefPubMedGoogle Scholar
  55. Sharma A, Shaw SR (2012) Efficacy of risperidone in managing maladaptive behaviors for children with autistic spectrum disorder: a meta-analysis. J Pediatr Health Care 26:291–299CrossRefPubMedGoogle Scholar
  56. Simon V, Czobor P, Balint S, Meszaros A, Bitter I (2009) Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. Br J Psychiatry 194:204–211CrossRefPubMedGoogle Scholar
  57. Sonuga-Barke EJ, Brandeis D, Cortese S, Daley D, Ferrin M, Holtmann M et al (2013) Nonpharmacological interventions for ADHD: systematic review and meta-analyses of randomized controlled trials of dietary and psychological treatments. Am J Psychiatry 170:275–289CrossRefPubMedGoogle Scholar
  58. Tanaka Y, Rohde LA, Jin L, Feldman PD, Upadhyaya HP (2013) A meta-analysis of the consistency of atomoxetine treatment effects in pediatric patients with attention-deficit/hyperactivity disorder from 15 clinical trials across four geographic regions. J Child Adolesc Psychopharmacol 23:262–270CrossRefPubMedGoogle Scholar
  59. Taylor E, Dopfner M, Sergeant J, Asherson P, Banaschewski T, Buitelaar J et al (2004) European clinical guidelines for hyperkinetic disorder – first upgrade. Eur Child Adolesc Psychiatry 13(Suppl 1):I7–I30PubMedGoogle Scholar
  60. Van der Oord S, Prins PJ, Oosterlaan J, Emmelkamp PM (2008) Efficacy of methylphenidate, psychosocial treatments and their combination in school-aged children with ADHD: a meta-analysis. Clin Psychol Rev 28:783–800CrossRefPubMedGoogle Scholar
  61. WHO (1992) The ICD-10 classification of mental and behavioral disorders: clinical descriptions and diagnostic guidelines 1992; diagnostic criteria for research 1993. Geneva 1992Google Scholar
  62. Zaman R (2015) Transcranial magnetic stimulation (TMS) in Attention Deficit Hyperactivity Disorder (ADHD). Psychiatr Danub 27(Suppl 1):530–532Google Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Department of Psychology, Developmental Brain-Behaviour LaboratoryUniversity of SouthamptonSouthamptonUK
  2. 2.IRCCS Stella MarisScientific Institute of Child Neurology and PsychiatryCalambroneItaly
  3. 3.The Child Study Center at NYU Langone Medical CenterNew YorkUSA

Personalised recommendations